Illinois CancerCare recently contributed to a new FDA-approved cancer treatment that promises better results than chemotherapy. | Stock photo
Illinois CancerCare recently contributed to a new FDA-approved cancer treatment that promises better results than chemotherapy. | Stock photo
Illinois CancerCare recently contributed to a phase 3 clinical trial that has led to FDA approval of a treatment for chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that promises better results and fewer side effects than current treatment with chemotherapy.
Illinois CancerCare enrolled six participants in the national trial of Ibrutinib and Rituximab as a combination therapy in the initial treatment of CLL and SLL, a release issued on the Peoria Area Chamber website said.
“Important advancements such as this are made possible by patients that participate in research," Jennifer Anderson, Illinois CancerCare’s clinical research operations manager, said in the release. "Illinois CancerCare significantly contributed to this groundbreaking FDA approval by enrolling six patients in the E1912 clinical trial.”
“NCI sponsored, community-based research trials continue to play a major role in moving cancer treatments forward,” Anderson further said in the release. “Additionally, donations from Illinois CancerCare Foundation help fund our research program. With ongoing decreases in NCI research funding nationwide, our Foundation has been instrumental in ensuring that our patients do not miss out on life-changing trials such as this.”
Alerts Sign-up